This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
Save the dateMarch 17–19, 2025 | Milan, Italy

Guillem Laporta
Partner at Ysios Capital


Guillem is Partner at Ysios Capital, where he joined in 2018. He is responsible for evaluating investment opportunities and representing Ysios at the board of directors of portfolio companies.

Guillem has over 10 years of venture capital experience. Prior to joining Ysios, he worked at the Edmond de Rothschild Group in Paris (now Andera Partners). There he was involved in the execution of several investments in Europe and the United States, including successful companies such as Reviral (sold to Pfizer), Axonics Modulation (Nasdaq: AXNX, $3B market cap) and Sanifit (sold to Vifor). Prior to this, he was an analyst at Caixa Capital Risc, where he was part of the life science team.

Guillem is a CFA charterholder. He also holds bachelor’s degrees in Biotechnology from the Universitat Autonoma de Barcelona, and in Business Administration from the Universitat Pompeu Fabra.

Board positions

Guillem currently serves on the Board of VarmX.

Agenda Sessions

  • Closing the gap: the imperative for women’s health in biopharma